ASND vs. LEGN, CERE, VKTX, ROIV, JAZZ, ITCI, ELAN, CYTK, IONS, and CTLT
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
In the previous week, Ascendis Pharma A/S had 14 more articles in the media than Legend Biotech. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 2 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 0.51 beat Legend Biotech's score of 0.25 indicating that Legend Biotech is being referred to more favorably in the media.
Ascendis Pharma A/S received 352 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.65% of users gave Ascendis Pharma A/S an outperform vote while only 63.33% of users gave Legend Biotech an outperform vote.
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Legend Biotech has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Legend Biotech presently has a consensus target price of $82.64, indicating a potential upside of 79.12%. Ascendis Pharma A/S has a consensus target price of $173.88, indicating a potential upside of 29.58%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Ascendis Pharma A/S.
Legend Biotech has higher earnings, but lower revenue than Ascendis Pharma A/S. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Ascendis Pharma A/S has a net margin of -152.68% compared to Ascendis Pharma A/S's net margin of -181.75%. Ascendis Pharma A/S's return on equity of -37.19% beat Legend Biotech's return on equity.
Summary
Legend Biotech beats Ascendis Pharma A/S on 10 of the 18 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
